Substance / Medication

Ciclopirox olamine

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis.
Ratnavel Ravi C, Squire Ruth A, Boorman Graham C · J Dermatolog Treat · 2007
PMID: 17520465RCT
MODELLING AND BIOPHARMACEUTICAL EVALUATION OF CICLOPIROX OLAMINE GELS.
Mazurkeviciute Agne, Ramanauskiene Kristina, Askiene Marija Iv et al. · Acta Pol Pharm · 2017
PMID: 29624259Observational
Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine.
Shaikh Karimunnisa Sameer, Chellampillai Bothiraja, Pawar Atmaram Pandurang · Drug Dev Ind Pharm · 2010
PMID: 20196642Observational
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.
Eberhard Yanina, McDermott Sean P, Wang Xiaoming et al. · Blood · 2009
PMID: 19589922Observational
Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.
Kokjohn Katrina, Bradley Mary, Griffiths Brian et al. · Int J Dermatol · 2003
PMID: 12895182Observational
Congenital candidal onychomycoses: effective cure with ciclopirox olamine 8% nail lacquer.
Sardana K, Garg V K, Manchanda V et al. · Br J Dermatol · 2006
PMID: 16445808Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ciclopirox olamine (substance)
SNOMED CT
70169009
UMLS CUI
C0126169

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.